GlassScriptPhysician profile
Eduardo J Guzman
NPI 1982610887
$1,167.60
in general payments reported to CMS, 2019-2025
16 companies · $582 in 2025
The $582 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $169 · 2021: $230 · 2024: $35.49 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $617.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $352.92 | 2020-2025 | |
| Lundbeck LLC | $217.63 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $186.52 | 2025 | Myfembree |
| Takeda Pharmaceuticals U.S.A., INC. | $95.61 | 2020-2021 | |
| Minerva Surgical, INC | $56.81 | 2019 | |
| Gilead Sciences, INC. | $45.45 | 2019 | |
| Amgen INC. | $37.50 | 2020 | |
| Axsome Therapeutics, INC. | $25.55 | 2025 | Auvelity |
| Roche Diagnostics Corporation | $25.15 | 2019 | |
| Amag Pharmaceuticals, INC. | $24.06 | 2019 | |
| Abbvie INC. | $21.27 | 2021 | |
| Exeltis, USA INC. | $19.22 | 2024 | Slynd |
| Neurocrine Biosciences, INC. | $16.49 | 2025 | |
| Pfizer INC. | $16.27 | 2024 | |
| Ethicon US, LLC | $13.71 | 2025 | Dermabond |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $13.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.